Neuronetics (STIM) Q4 2025 Earnings Transcript

Q4 revenue $41.8M (reported +86% YoY; pro forma +23%), with NeuroStar revenue $18.3M and clinic revenue $23.5M; Q4 operating cash flow turned positive at $0.9M and EBITDA improved to -$4.3M (from -$11.0M). Management set 2026 revenue guidance of $160–$166M (>9% growth), gross margin guidance 47%–49%, and expects full-year operating cash flow of -$13M to -$17M with positive cash flow in H2; operating expense guidance $100M–$105M including ~$8.5M stock-based comp. Company completed $5.0M principal repayment to Perceptive (pro forma cash ~$29.1M), announced a CEO transition effective Mar 23, 2026, and highlighted commercialization prep with COMPASS (COMP360 NDA targeted year-end). Key risks: U.S. Attorney investigation into pre-acquisition billing practices and lower-margin Greenbrook clinic mix that pressured gross margin (Q4 52% vs prior 66%).

Analysis

Neuronetics' integration of a national clinic network creates a rare go-to-market asset for REMS‑style therapies: an operating footprint that materially shortens commercialization timelines for biotechs that otherwise face 18–24 month clinic-readiness lifts. That creates optionality beyond device sales — a B2B services and revenue-share channel (benefits investigation, intake-as-a-service, REMS operations) that could reprice the company from a pure med‑device multiple to a higher multiple growth healthcare services comp if management monetizes it deliberately.

Operational levers (workflow digitization, AI in claims, provider outreach) imply unit‑economics expansion that is largely non-linear: incremental automation can cut revenue-cycle headcount and improve first‑pass claim acceptance, turning low-margin clinic throughput into disproportionately higher contribution margins. Conversely, pushing capital sales into new customer segments accelerates installed-base growth but increases near‑term working capital and warranty/servicing exposure — a timing mismatch between margin improvement and cash burn that makes the next two quarterly prints high‑variability events.

Key external catalysts are binary and time‑concentrated: third‑party approvals or payer coverage decisions for novel TRD therapies can open a multi‑year demand wave, but reimbursement lag and competitive hospital/MSO responses can compress take rates and pricing. Finally, legal and regulatory overhangs are asymmetric risks that can slow partnerships and raise compliance costs; investors should treat corporate‑action optionality (partnership rollouts, B2B pricing) as primary drivers of upside, and near‑term cash/covenant dynamics as primary downside triggers.

Key Decisions for Investors

• STIM (long, staged): Initiate a small core long position (1–2% of portfolio) now and add into confirmed operational inflection points — specifically: 1) a Q1 cash‑flow improvement print and 2) a new payer coverage win for a REMS therapy. Target 12‑month upside 40–80%; hard stop at 25% below entry to limit legal/regulatory tail risk.
• STIM (hedged equity): If executing a larger exposure (3–5%), use a collar (buy equity + buy 6‑9 month protective puts at ~25% OTM and sell 6‑9 month calls ~30–40% OTM) to cap cost while retaining upside to commercialization catalysts.
• CMPS (options speculative): Buy 9–12 month call spreads on COMPASS (long-dated calls or LEAP call spread) to capture NDA/approval optionality into year‑end while limiting premium decay. Size small (0.5–1% portfolio) — risk limited to premium; reward asymmetric if approval + payer rollout accelerates.
• Event-driven pair (medium risk): Pair a long STIM position with a ~3–6 month put or reduced size until Q1 cash conversion is proven; this converts binary regulatory/commercial risk into defined downside while preserving upside from service monetization and COMPASS commercialization.